HIV-AIDS

MBBS, 3rd year



Introduction

- HIV was first Identified in 1981 in USA among homosexuals
- In 1983, French investigator named Lymphadenopathy associated virus (LAV).
- In 1984 virus was isolated by Gallo and coworkers from national institute of health in United States.
- They named Human T-cell Lymphotropic virus III (HTLV-III).

Contd.

- Thailand was the first country in the SEAR to report a case of AIDS, in 1984.
- In 1986, a new strain of HIV was isolated in West African patient with AIDS which is called HIV-2.
- In May 1986, international committee on taxonomy gave a new name called Human immune deficiency virus.
- Since its identification, HIV/AIDS is devastating disease of mankind

Etiology

- Human Immuno Deficiency Virus
- Size: 1/10,000th of a millimeter in diameter.
- It is a protein capsule containing two short strands of genetic material (RNA) and enzymes.
- Two types: HIV-1 and HIV-2


Reservoir of infection

- Cases and carriers.
- Once a person is infected, virus remains lifelong
- It can be transmitted even if the person is symptoms less.



- Virus has been found in greatest concentration in blood, semen and CSF.
- Lower concentration have been detected in tears, saliva, breast milk, urine, and cervical and vaginal secretion.
- To date, only blood and semen have been conclusively shown to transmit the virus.

Pathogenesis of HIV infection



Host factors:

- Age: Most cases have occurred among sexually active persons aged 20-49
- Sex: In Africa: More female are affected
- In North America, Europe and Australia, about 51 per cent of cases are homosexual or bisexual men.
- In Nepal: 2:1

Risk Groups for HIV infection

- Sex workers
- IDUs
- Clients of sex workers
- Labor migrant / Transport workers
- MSM
- Partners of migrants / house wives
- Street children
- Military, police
- Health care workers

PHASES OF HIV INFECTION

- 1. Phase 1 (3-12 weeks)
- Acute HIV syndrome
- Sore throat
- Fever
- Skin rash
- Meningitis
- High viremia



- Middle chronic Phase(10-12 years)
- Competition between HIV and host immune system
- Patient asymptomatic or has mild symptoms
- Moderate viremia



- Full blown AIDS
- Severe immuno- suppression
- Drop in CD4 count below 200/µI (normal count: > 950 CD4 cells/µI }
- High viremia



- Major
- Weight loss >10% body weight
- Chronic diarrhea >1 months duration
- Prolonged fever >1 month
- 2. Minor
- Recurrent oral-pharyngeal candidiasis
- Persistent generalized lymphadenopathy
- Persistent cough>1 month
- Recurrent herpes zoster

Diagnosis is made on the basis of presence of at least two major and one minor sign



Mode of Transmission:

HIV is transmitted:



During sexual contact

Unprotected sex

Anal (10 times higher risk)

Vaginal

Oral

- transmission from male to female is more (twice) as compared to female to male.
- STDs facilitate for transmission of HIV.



HIV is transmitted: Through infected blood



 Sharing needles

 Use of contaminated needles and syringes



HIV is transmitted:



Though infected blood / blood products

 Transfusion of HIV infected blood or blood products



HIV is transmitted:

From mother to child



- During pregnancy
- During child birth
- Through breast feeding



Lab diagnosis

Direct tests

- ELISA (enzyme-linked-immunosorbent serologic assay)
- Recombinant DNA techniques
- Viral isolation in culture
- PCR

Indirect Tests

- CD4 counts
- Lymphopenia
- Lymphnode biopsy

Incubation period:

 Current data suggest that the incubation periods is uncertain, (from a few months to 10 years or even more)

Severity of the epidemics determined by:

- 1. % of adult men visiting sex workers (5% in Hong Kong, 9% in China, 20% in Thailand and Cambodia)
- 2. Number of sex workers' clients per night
- 3. % of sex workers using condoms consistently
- 4. % of injecting drug users who are clients of sex workers



- Raising awareness
 - To be faithful to partner
 - Use of Condom
 - IDUs should be informed not to share needle and syringes.
 - Distribution of IEC materials.
 - Advertisement from different media or channels.

Contd.

- Prevention of blood borne HIV Transmission
- People in high-risk groups should be urged to refrain from donation of blood, body organs, sperm or other tissues.
- The donors blood should be screened for HIV 1 and HIV 2 before transfusion.
- Strict sterilization techniques should be applied to the hospitals and clinics.
- Avoid injections unless they are absolutely necessary.
- Rehabilitation of HIV/AIDS cases,

HIV/AIDS – Global and Regional scenario

- 34 million people living with HIV.
- 26 million are eligible for antiretroviral therapy, under WHO 2013 consolidated ARV guidelines.
- At the end of 2012, about 10 million people had access to ARV therapy.

- HIV claimed more than 25 million lives over the past three decades.
- Sub-Saharan Africa is the most affected region, with nearly 1 in every 20 adults living with HIV.
- 69% per cent of all people living with HIV are living in this region.

WHO


HIV situation in Nepal

- In Nepal, first case of HIV/AIDS was diagnosed in 1988.
- The prevalence of HIV/AIDS is 0.3/1000 among general population NCASC 2012).
- Nepal succeed in decreasing new HIV infections by more than 25% in last one decade: UNAIDS report on the global AIDS epidemic.


HIV cases in Nepal

| HIV Cases as of 15-Dec-2012 | | | | | |
|-----------------------------|--------|----|--------|--|--|
| Male | Female | TG | Total | | |
| 13,718 | 7,817 | 16 | 21,551 | | |

Figure 4: Declining HIV prevalence among the adult (15-49) population group in Nepal: 1985-2015 (NCASC, 2011)




gure 7: Scaling-up of Pivi ICI Services in Nepal: 2006-2011




Nepal 2011 HIV Infections Estimates

| Population Groups | Estimated HIV Infections (15-49 years) | Proportio n (%) |
|--|--|--------------------|
| People who Inject Drugs (PWIDs) | 939 | 2.2 |
| MSW, TG and Clients | 3,099 | 7.2 |
| Other MSM who do not sell and/or buy sex | 6,245 | 14.4 |
| Female Sex Workers (FSWs) | 647 | 1.5 |
| Clients of FSWs | 1,915 | 4.4 |
| Male Labour Migrants | 11,672 | 27.0 |
| Remaining Male Population | 6,914 | 16.0 |
| Remaining Female Population | 11,808 | 27.3 |
| Total | 43,239 | 100.0 |

Estimated Number of HIV Infections and HIV Prevalence among Adults: 1985-2015



Routes of Transmission among Reported HIV cases, 2011



Why is Nepal vulnerable? (Determinants of HIV/AIDS in Nepal)

- Poverty
- Low education
- Gender inequalities
- Stigma and Discrimination
- Lack of adequate health care delivery
- Insurgency and insecurity
- Migration (Push and Pull factors)
- Alcoholism and drug abuse
- Women trafficking/child abuse
- Social traditions

Plan and policy implementation

| 198 | 8 Launch | ed th | e first National AIDS |
|-----|---------------------------|-------|-----------------------|
| | ntion and Control Program | | |
| | (short term) | | |

1990-1992 First Medium Term Plan

1993-1997 Second Medium Term Plan

1993 National Policy on Blood safety

1995 Adopted National Policy on HIV/AIDS

1997–2001 Strategic Plan for HIV/AIDS Prevention

2002-2006 National HIV/AIDS Strategic Plan

2003-2007 National HIV/AIDS Operational Plan

2006 National HIV/AIDS Strategic Plan (2006-11)

2010 National policy on HIV and STI 2010

Vision and Goal of National policy on HIV and STI 2010

 Vision: To establish Nepal free of HIV, AIDS and STIs society

 Goal: To ensure the people's rights to health by reducing impact of HIV among people by reducing HIV incidence

Key Policy Points

- Policy making and planning
- Prevention, treatment,
 care and support
- Harm reduction
- Rights and confidentiality
- Rehabilitation and social integration

- Bi- and multi-lateral approach
- Structural arrangement
- Research
- Community based programme
- Financial management
- Monitoring and evaluation



- HIV and AIDS " is still seen as 'health' issue not a social issue.
- Multi-sectoral partnership needs to be further strengthened
- Prevailing Stigma and Discrimination (SWs, MSM, IDUs)
- 'Not my problem!' Attitude among high level decision makers or programmers.



- Gap in knowledge and behaviour change.
- Legal implications on IDUs.
- Access to STI, HIV and AIDS and OIssevices.
- Scaling up of program including ART, PMTCT.
- Community and home based care and support for infected and affected needs to be addressed.

PMTCT in Nepal

- Comprehensive PMTCT service started in Nepal from February 2005.
- Government provides free ARV drugs and testing for the babies free of cost from 18 months.
- There are 21 PMTCT sites, of which 20 sites offer Pediatric ART. There are 2 (Accham and Sunsari) districts implementing CB PMTCT programme.

Antiretroviral Treatment

- Nucleoside analogue
- Introduced in 1987
- Zidovudine (AZT), didanosine 'ddl'(Videx), zalcitabine 'ddc'(Hivid), stavudine etc.
- These are not effective if used alone.
- These drugs slow HIV growth.
- Also prevents transmission of HIV from an infected mother to her newborn.

2. protease inhibitors


- More powerful than previous, producing dramatic decreases in HIV levels in the blood.
- This reduced viral load, in turn, enables
 CD4 cell levels to skyrocket.
- Ritonavir (Norvir), indinavir (Crixivan), nelfinavir (Viracept), amprenavir (Agenerase), etc.

Contd.

- 3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs):
- Introduced in 1996
- Three NNRTIs are available: nevirapine (Viramune), delavirdine (Rescriptor), and efavirenz (Sustiva).
- These drugs bind directly to reverse transcriptase, preventing the enzyme from converting RNA to DNA.
- NNRTIs work best when used in combination with nucleoside analogues.

Atripla

- A new combined drug, introduced in July 2006.
- Combination of Sustiva (the NNRTI efavirenz) and Truvada (the NRTIs emtricitabine and tenofovir) in a special formulation.



- PEP should be started within hours.
- Its for accidental niddle exposure to HIV among health care workers.
- It decrease the chances of being infected by nearly 80%.

